Inhalation Wednesday, April 25, 2018
Skip Navigation LinksHome) Webinar 2017-09/12 Biopharmaceutical Consideration
Inhalation is the only technical publication devoted exclusively to readers involved in development and production of pulmonary or nasal delivered pharmaceuticals.

Biopharmaceutical Considerations in Dry Powder Aerosol Drug Delivery

Tuesday, September 12, 2017

Time:  12:00 PM (Noon) – 1:30 PM ET

Presenter:  Anthony J. Hickey, PhD, DSc. Distinguished RTI Fellow, Research Triangle Institute and Emeritus Professor of Molecular Pharmaceutics, Eshelman School of Pharmacy and Adjunct Professor Biomedical Engineering, School of Medicine, The University of North Carolina at Chapel Hill.

Guest Moderator:  Daryl L. Roberts, PhD. President, Applied Particle Principles, LLC.

Webinar Cost: FREE

Webinar Details:  The benefits of dry powder inhaler drug products in disease management have been recognized with the increasing numbers of new technologies introduced over the last 20 years. Our knowledge and understanding of the critical attributes influencing the quality and performance of these unique drug products has evolved. The role of the physico-chemical properties has been a major focus of research endeavors and, while there are no predictive models, many of the key factors influencing powder behavior and aerosol delivery are understood.

The drug product performance interface between the patient and the device dictates lung deposition and clearance of an aerosol. Emphasis on in vitro/in vivo correlation (IVIVC) to predict the potential therapeutic outcome of drug therapy is based on product performance in response to patient effort, anatomy and physiology. The prospect of an inhaled Biopharmaceutical Classification System (BCS) has been explored. The foundation of a BCS will be key physical and biological parameters. Therefore, a crucial element of any IVIVC or BCS approach is an understanding of the interaction of the formulation with the inspiratory airflow and the implications for site of deposition and subsequent disposition. These interactions and their implications will be considered in terms of aerodynamic particle size distribution, delivered dose, rate of delivery, sites of deposition and clearance mechanisms.

Presenter Information:  Dr. Anthony J. Hickey is Distinguished RTI Fellow, at the Research Triangle Institute, Emeritus Professor of Molecular Pharmaceutics of the Eshelman School of Pharmacy, and Adjunct Professor Biomedical Engineering in the School of Medicine, at the University of North Carolina at Chapel Hill. He is the recipient of multiple awards and has published numerous papers and chapters in the pharmaceutical and biomedical literature. He has edited five texts on pharmaceutical inhalation aerosols and co-authored three others. He is founder of Cirrus Pharmaceuticals, Inc., acquired by Kemwell Pharma; founder of Oriel Therapeutics, Inc., acquired by Sandoz and founder of Astartein, Inc. Dr. Hickey has been a member of the Pharmaceutical Dosage Forms Expert Committee of the United States Pharmacopeia, Chair of the sub-committee on Aerosols and formerly Chair of the Aerosols Expert Committee of the USP. He also conducts a multidisciplinary research program in the field of pulmonary drug and vaccine delivery for treatment and prevention of a variety of diseases.

Moderator Information:  Dr. Daryl L. Roberts is co-inventor of the Next Generation Impactor (NGI) and has developed and published practical methods to allow impactor users to determine whether new and used impactors are suitably within compendial specifications. He has helped develop a family of labor-saving equipment that assists users to recover drug products from impactors in a manner suitable for quantitative analysis. Dr. Roberts is the instructor for the laboratory portion of the ISAM Aerosol School, a guest member of the Impactor Subcommittee of the European Pharmaceutical Aerosol Group, a contributor to the USP Aerosol Experts Committee, on the editorial board of Inhalation, and a regular contributor and reviewer of articles for AAPS Pharm. Sci. Tech., Aerosol Science and Technology, and Drug Delivery to the Lungs (DDL).

Can’t attend?  If you want to view the webinar but cannot attend the live event, please register in advance. That will enable you to watch an archived version of the entire webinar and Q&A session online for up to 30 days after the event at a time most convenient to your schedule.

PDH Information:  If you are working on a certification or licensing program that allows Professional Development Hours, CSC Publishing Inc. will (upon request) provide a Certificate of Participation for educational webinars presented by Inhalation. One certificate per registered participant will be sent if the webinar is viewed. Please check with your employer or local agency to confirm their specific PDH requirements. In many cases, our educational webinars will contribute toward these hours.

Visit our sponsors:

      Copyright 2018, CSC Publishing Inc. ALL Rights Reserved * Privacy policy